Chugai Pharmaceutical Co., Ltd.는 자회사들과 함께 일본 및 해외에서 의약품의 연구, 개발, 제조, 판매, 수입 및 수출을 영위합니다. 이 회사는 Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, Tecentriq 등의 항암제를 제공하며, 인간화 항인간 IL-6 수용체 단일클론 항체인 Actemra, 면역억제제인 CellCept, pH 의존적 결합 인간화 항IL-6 수용체 단일클론 항체인 Enspryng, 척수성 근위축증 치료제인 Evrysdi, 항응고 인자 IXa/X 인간화 이중특이성 단일클론 항체인 Hemlibra, 적혈구 생성 촉진제인 Mircera, pH 의존적 결합 인간화 항보체(C5) 단일클론 항체인 PiaSky, 항
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.